64/100BMedline return on equity (ROE)What is return on equity (ROE)? Return on equity (ROE) is a year of net income divided by shareholders' equity: the profit a company makes on each dollar its owners have in it.
Medline's return on equity is 7.42%: net income of 876.00M USD over the last twelve months on shareholders' equity of 11.80B USD.
- Today
- 7.42%
- Average, 5 years
- 8.35%
- Low, 5 years
- 6.65%
- High, 5 years
- 10.78%
ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = 876.00M ÷ 11.80B = 7.42%
Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.
What drives Medline's return on equity?What is DuPont analysis? DuPont analysis splits return on equity into three parts: profit margin, asset turnover and the equity multiplier. It shows whether a high ROE comes from profits, from using assets well, or from debt.
- FY20254.1% × 0.74 × 3.58 = 10.8%
- FY20244.7% × 0.71 × 2.18 = 7.3%
- FY20231.0% × 0.64 × 2.13 = 1.4%
The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.
ROE (return on equity) by year and by quarter
| Fiscal year | Period ending | ROE (return on equity) | Net income | Shareholders' equity |
|---|---|---|---|---|
| Today | 7.42% | 876.00M | 11.80B | |
| FY2025 | 31 Dec 2025 | 10.79% | 1.16B | 10.74B |
| FY2024 | 31 Dec 2024 | 7.26% | 1.20B | 16.52B |
| FY2023 | 31 Dec 2023 | 1.38% | 234.00M | 16.98B |
| FY2022 | 31 Dec 2022 | — | -25.00M | — |
| Quarter | Period ending | ROE (return on equity) | Net income | Shareholders' equity |
|---|---|---|---|---|
| Q3 FY2026 | 26 Sept 2026 | 7.42% | 876.00M | 11.80B |
| Q2 FY2026 | 27 Jun 2026 | 6.65% | 770.00M | 11.57B |
| Q1 FY2026 | 31 Mar 2026 | 8.55% | 964.00M | 11.27B |
| Q4 FY2025 | 31 Dec 2025 | 10.78% | 1.16B | 10.74B |
| Q3 FY2025 | 30 Sept 2025 | — | — | 17.14B |
| Q2 FY2025 | 30 Jun 2025 | — | — | 16.95B |
| Q1 FY2025 | 28 Mar 2025 | — | — | 16.16B |
| Q3 FY2024 | 30 Sept 2024 | — | — | — |
| Q2 FY2024 | 30 Jun 2024 | — | — | — |
Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.
See also:P/E ratio,Market cap,P/S ratio,Debt to equity,Current ratio,All ratios
Common questions about Medline's ROE
Source: Financial Modeling Prep